Free Trial
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

Pulmatrix logo
$5.40 +0.01 (+0.19%)
Closing price 04/15/2025 03:59 PM Eastern
Extended Trading
$5.47 +0.07 (+1.30%)
As of 04/15/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pulmatrix Stock (NASDAQ:PULM)

Key Stats

Today's Range
$5.31
$5.60
50-Day Range
$5.39
$10.02
52-Week Range
$1.72
$10.40
Volume
11,923 shs
Average Volume
132,092 shs
Market Capitalization
$19.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Remove Ads

Pulmatrix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

PULM MarketRank™: 

Pulmatrix scored higher than 12% of companies evaluated by MarketBeat, and ranked 911th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pulmatrix.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmatrix is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmatrix is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmatrix has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pulmatrix's valuation and earnings.
  • Percentage of Shares Shorted

    1.01% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently decreased by 2.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pulmatrix does not currently pay a dividend.

  • Dividend Growth

    Pulmatrix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.01% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently decreased by 2.64%, indicating that investor sentiment is improving.
  • News Sentiment

    Pulmatrix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Pulmatrix this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmatrix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.62% of the stock of Pulmatrix is held by insiders.

  • Percentage Held by Institutions

    Only 11.84% of the stock of Pulmatrix is held by institutions.

  • Read more about Pulmatrix's insider trading history.
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

Why "Made in America" could cost millions their job
President Trump promised tariffs will bring jobs home... that factories will soon be full again... and that American workers will thrive. But buried in the fine print is a dark truth... Those factories are filled with a much different kind of worker.
See More Headlines

PULM Stock Analysis - Frequently Asked Questions

Pulmatrix's stock was trading at $6.98 at the beginning of the year. Since then, PULM shares have decreased by 22.6% and is now trading at $5.40.
View the best growth stocks for 2025 here
.

Pulmatrix, Inc. (NASDAQ:PULM) released its earnings results on Friday, March, 21st. The biotechnology company reported ($0.54) EPS for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative trailing twelve-month return on equity of 45.97%.

Pulmatrix's stock reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

Last Earnings
3/21/2025
Today
4/16/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PULM
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,120,000.00
Pretax Margin
-96.51%

Debt

Sales & Book Value

Annual Sales
$7.81 million
Price / Cash Flow
N/A
Book Value
$4.93 per share
Price / Book
1.10

Miscellaneous

Free Float
3,629,000
Market Cap
$19.71 million
Optionable
Not Optionable
Beta
1.55

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:PULM) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners